Weight-Loss Injections:
Complete Guide, Risks & Care

1. What weight-loss injections are

"Weight-loss injections" (or "weight-loss pens") is the popular name for a class of injectable medicines, given just under the skin (subcutaneously), that support weight management by acting on hormones that regulate appetite and satiety. Most belong to the class of GLP-1 receptor agonists (and, in the case of tirzepatide, the GIP receptor too) — the same hormones the gut naturally releases after meals.

It is important to separate the marketing name from the clinical reality: these are not "belly-fat burners," but continuous-use medicines originally developed for type 2 diabetes and, more recently, also approved to treat obesity. They work best combined with dietary changes, physical activity and professional follow-up — and replace none of those pillars.

2. How they work in the body

GLP-1 is a hormone released by the gut when we eat. These medicines mimic it in a long-lasting way, producing four main effects:

• Increased satiety — acting on appetite-related brain areas, reducing hunger and cravings for high-calorie foods.
• Slower stomach emptying — food stays longer in the stomach, prolonging fullness.
• Smart insulin release — stimulating insulin only when glucose is high, helping blood-sugar control with low hypoglycemia risk.
• Less glucose production by the liver — improving metabolic control.

In practice, people tend to eat less and feel less hungry. Weight loss is a consequence of these effects — not a magic "fat-melting" action.

3. Main medicines available

A common source of confusion: Ozempic is labeled for diabetes, while Wegovy (same ingredient, higher dose) is the one approved specifically for obesity. Using Ozempic purely for weight loss, without diabetes, is "off-label" and should only happen under medical judgment and responsibility.

4. Real efficacy: what to expect (no miracles)

• Semaglutide 2.4 mg (Wegovy): about 15% of body weight lost over 68 weeks (STEP 1 trial).
• Tirzepatide 15 mg (Mounjaro/Zepbound): up to 22.5% over 72 weeks (SURMOUNT-1).
• Liraglutide (Saxenda): more modest, around 5–8%.

These are averages, achieved alongside lifestyle changes. None of these trials showed weight loss without proper diet and exercise. Be skeptical of any promise to "lose X kilos in a week."

5. Who they are for — and who they aren't

Generally, and always under medical assessment, they are considered for people with obesity (BMI ≥ 30), or overweight (BMI ≥ 27) plus a comorbidity such as type 2 diabetes, hypertension, sleep apnea or dyslipidemia.

They are contraindicated or need extra caution with: personal/family history of medullary thyroid cancer or MEN2 (absolute); history of pancreatitis (relative); pregnancy and breastfeeding; gallbladder disease or eating disorders. They are not meant for losing a few cosmetic pounds without a clinical indication.

6. Tests before and during use

• Before starting: weight, height and BMI; waist circumference; fasting glucose and HbA1c; full lipid profile, watching triglycerides (very high levels raise pancreatitis risk); kidney and liver function; and personal/family history (thyroid, pancreas, gallbladder, eating disorders).
• During treatment: tracking weight and ideally body composition (to watch muscle loss); assessing adverse effects; reinforcing diet and exercise; and periodic metabolic review.

7. Pancreas risk and regulatory alerts

• There is a risk of acute pancreatitis, but it is low — about 2 to 3 cases per 1,000 people — and most large reviews do not confirm a strong causal link.
• Regulators worldwide (FDA, EMA and, in Brazil, ANVISA — which reinforced its alert in 2026) keep this risk under active monitoring. The risk is already listed on the labels; alerts reinforce safety rather than ban use.
• Much of the abdominal pain in these patients comes from common, treatable causes: gallstones (rapid weight loss favors them), alcohol and very high triglycerides.

8. Side effects, muscle loss and "Ozempic face"

The most common effects are gastrointestinal: nausea, vomiting, diarrhea and constipation. They tend to be stronger at the start and improve with gradual dose titration. Other key points:

• Muscle loss — part of the weight lost is muscle, not just fat. Resistance exercise and adequate protein are essential.
• "Ozempic face" — rapid weight loss can leave the face looser and older-looking.
• Gallstones — more common with fast weight loss.
• Gallbladder issues, retinopathy (in diabetics) and injection-site reactions should be monitored.

9. Medical follow-up and the risk of unsupervised use

This is the most important point. A worrying trend is unsupervised use, with self-adjusted doses, purchases from untrustworthy sources and compounded versions without regulatory registration. Risks include wrong dosing, products without quality/sterility guarantees, ignored contraindications, worsening of eating disorders and no monitoring of warning signs. Safe treatment requires individualized prescription, correct titration and follow-up visits.

10. What happens when you stop

Because obesity is chronic, stopping usually leads to partial weight regain, especially if habits have not changed. This is not "failure" — the medicine works while active, like drugs for blood pressure or cholesterol. Whether to continue, adjust or stop should always be decided with your doctor.

11. Frequently asked questions

Do they harm the pancreas?
The pancreatitis risk exists but is low, with no strong proven causal link. Medical follow-up and seeking care for severe abdominal pain are essential.

Do I need a prescription?
Yes — these are prescription medicines requiring assessment and monitoring.

Does the weight come back if I stop?
Usually partly, because obesity is chronic. Stopping should be decided with your doctor.